ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

クロルメザノン

Chlormezanone

HCID 2717
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
102818-66-6
標準SMILES
CN1C(=O)CCS(=O)(=O)C1c1ccc(Cl)cc1
InChIKey
WEQAYVWKMWHEJO-UHFFFAOYSA-N
分子式
C11H12ClNO3S
平均分子量
273.74 g/mol
単同位体質量
273.02264192

概要

Chlormezanone is a 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions. It has a role as an anxiolytic drug, an antipsychotic agent and a muscle relaxant. It is a lactam, a sulfone, a 1,3-thiazine and a member of monochlorobenzenes.

名称と識別子

優先名称
Chlormezanone
IUPAC
2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one
現地名
クロルメザノン
英語名
Chlormezanone
分子式
C11H12ClNO3S
分子量
273.74

名称と別名

chlormezanone80-77-3ChlormethazanoneTrancopalChlormethazoneChlormezanonClormetazanoneClormetazonPhenaroldl-ChlormezanoneBanabinClorilax
名称をさらに表示
クロルメザノンバナビン-シンチアルタナホールロバックミオ-セドリランシルアリナン2-(4-クロロフェニル)テトラヒドロ-3-メチル-4H-1,3-チアジン-4-オン1,1-ジオキシドトランコパルリラッソールレクサントランサナートフェナロールクロルメタザノンリランキルスポトラントランコパール2-(4-クロロフェニル)-3-メチル-4-オキソテトラヒドロ-2H-1,3-チアジン1,1-ジオキシドクロルメザノン (JAN)リラキルLobakRilaxAlinamMuskelwin4692FENAROLMio-Sed
MiorilaxRilansylRilaquilRilassolSupotranTanafolBisinaRexan

データベース識別子

CAS
102818-66-6、102818-67-7、80-77-3

物性

構造計算による物性補完中

XLogP
1.1
極性表面積
62.8 Ų
水素結合供与体数
0
水素結合受容体数
3
回転可能結合数
1
重原子数
17
形式電荷
0
複雑度
395

実験および物理化学的性質

LogP1.3
Color/FormCRYSTALS
Solubility · 3 件

SOL (% WT/VOL) @ 25 °C: LESS THAN 0.25% IN WATER, LESS THAN 1.0% IN 95% ETHANOL

FREELY SOL IN CHLOROFORM; SLIGHTLY SOL IN DIETHYL ETHER; SPARINGLY SOL IN N-HEXANE

1.61e+00 g/L

Human Drugs · 3 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Melting Point · 3 件

116.2-118.6

116.2-118.2 °C

116.2 °C

Physical DescriptionSolid
Collision Cross Section · 3 件

154.1 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Dataset: TOXCAST; Source Identifier: DTXSID3022798]

156.85 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

158.2 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 4 reports by companies from 2 notifications to the ECHA C&L Inventory.

危険有害性情報

Other Safety InformationIMAP assessments - 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

毒性情報

Interactions · 1 件

CHLORMEZANONE MAY LOWER TOLERANCE OF PATIENTS TO ALCOHOL...POSSIBLE ADDITIVE EFFECTS /WITH CHLORMEZANONE &/ CNS DEPRESSANTS SUCH AS ALCOHOL, PHENOTHIAZINES, BARBITURATES, NARCOTICS, OTHER PSYCHOTHERAPEUTIC AGENTS, & MONOAMINE OXIDASE INHIBITORS.

Toxicity Summary · 1 件

Chlormezanone binds to central benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways.

Signs and SymptomsSymptoms of overdose include drowsiness, weakness, nausea, dizziness, abdominal pain, cerebral oedema and renal tubular necrosis, hyperglycaemia and hypoglycaemia, liver damage, encephalopathy, coma and death.
Human Toxicity Excerpts · 4 件

化学と産業

薬理情報

ATC Code · 2 件

M - Musculo-skeletal system

QM - Musculo-skeletal system

PharmacodynamicsChlormezanone is a non-benzodiazepine muscle relaxant. It was discontinued worldwide in 1996 by its manufacturer due to confirmed serious and rare cutaneous reactions (toxic epidermal necrolysis).
Mechanism of Action · 3 件

Chlormezanone binds to central benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways.

NEURONAL CONDUCTION, NEUROMUSCULAR TRANSMISSION, & MUSCLE EXCITABILITY ARE NOT DEPRESSED EXCEPT AFTER NEARLY LETHAL DOSES. PROMINENT EFFECT...IS TO DEPRESS SPINAL POLYSYNAPTIC REFLEXES PREFERENTIALLY OVER MONOSYNAPTIC REFLEXES. /CENTRALLY ACTING MUSCLE RELAXANTS/

IN ABSENCE OF DEFINITIVE STUDIES IT APPEARS REASONABLE TO ASCRIBE BENEFICIAL EFFECTS...TO THEIR SEDATIVE PROPERTIES. /CENTRALLY ACTING MUSCLE RELAXANTS/

Metabolism/Metabolites · 2 件

CHLORMEZANONE...IS EXCRETED UNCHANGED IN HUMAN URINE & DOG BILE. FORMATION OF 4-CHLOROHIPPURIC ACID, MAJOR URINARY METABOLITE IN MAN, INVOLVES NON-ENZYMIC HYDROLYSIS, FOLLOWED BY OXIDATION & CONJUGATION OF 4-CHLOROBENZALDEHYDE PRODUCT OF HYDROLYSIS.

(14)C-CHLORMEZANONE, METABOLITES IN URINE OF RATS & MICE WERE P-CHLOROBENZOIC ACID, P-CHLOROHIPPURIC ACID, N-METHYL-P-CHLOROBENZAMIDE, 2-[N-METHYL-N-(P-CHLOROBENZOYL)]CARBAMOYLETHYLSULFONIC ACID, 3-SULFOPROPIONIC ACID & GLUCURONIDE OF P-CHLOROBENZOIC ACID.

MeSH Pharmacological Classification · 2 件

A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358)

関連反応

0 件
反応記録を作成
関連する反応はまだありません

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
PubChem CID
2717
DTXSID
DTXSID3022798
ChEMBL
CHEMBL1200714
ChEBI
CHEBI:3619
UNII
4BU37OM8KL、C14WB33Y0S、GP568V9G19
EC Number
201-307-4
融点
114 °C · 114 °C
沸点
534.5 · 534.5±50.0 °C(Predicted)
比重(密度)
1.2205 · 1.2205 (rough estimate)
屈折率
1.63 · 1.6300 (estimate)
貯蔵温度
Sealed in dry,Room Temperature
溶解性
クロロホルム(微量)、酢酸エチル(微量)、メタノール(微量)
外見
個体
酸解離定数(Pka)
-2.37 · -2.37±0.40(Predicted)
色
白色~淡黄色
Merck
14 · 14,2106
InChI
InChI=1S/C11H12ClNO3S/c1-13-10(14)6-7-17(15,16)11(13)8-2-4-9(12)5-3-8/h2-5,11H,6-7H2,1H3
InChIKey
WEQAYVWKMWHEJO-UHFFFAOYSA-N
SMILES
S1(=O)(=O)CCC(=O)N(C)C1C1=CC=C(Cl)C=C1
NISTの化学物質情報
Chlormezanone(80-77-3)

...COMMONLY PRODUCE DROWSINESS, DIZZINESS, HEADACHE, BLURRED VISION, WEAKNESS, LETHARGY, ATAXIA, & NYSTAGMUS. NAUSEA, VOMITING, HEARTBURN, & ABDOMINAL DISTRESS...ESP AFTER LARGE ORAL DOES. ...SKIN RASH & PRURITUS &, RARELY, ANAPHYLACTOID REACTIONS & LEUKOPENIA. /CENTRALLY ACTING MUSCLE RELAXANTS/

INCIDENCE OF UNTOWARD REACTIONS IS ABOUT 3% & MINOR IN NATURE...MALAISE, EXCITEMENT... PETECHIAE, OR ECCHYMOSES SOMETIMES DEVELOP; LIVER DAMAGE...OR ANGIONEUROTIC EDEMA ARE RARE.

LETHARGY & FLUSHING HAVE BEEN OBSERVED & JAUNDICE HAS OCCURRED RARELY.

...ORAL TOXICITY LESS THAN MEPROBAMATE, ZOXAZOLAMINE, OR METHOCARBAMOL. ... IN CLINICAL TRIALS ONLY 2.3% OF 4653 PT HAS SIDE EFFECTS... OVERDOSAGE UP TO 10 G HAS NOT CAUSED DEATH. EVEN LARGE AMT PRODUCE ONLY MILD SIDE EFFECTS.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Chlormezanone

vMost-DILI-concern

8

Withdrawn

DOI:10.1016/j.drudis.2016.02.015

Non-Human Toxicity ExcerptsIN CHRONIC LAB STUDIES ONLY ADVERSE EFFECT NOTED WAS ATAXIA, @ HIGHEST DOSAGE LEVEL.

安全データ

rtecs
XJ1050000
hs_code
2934.99.4400
Hazard Classifications
Acute Tox. 4 Oral
ストレージクラス
11 - Combustible Solids
有毒物質データの
80-77-3(Hazardous Substances Data)

Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.

Absorption, Distribution and Excretion · 2 件

RAPIDLY ABSORBED FROM GI TRACT...EFFECT WITHIN 15 TO 30 MIN...DURATION OF ACTION OF 4 TO 6 HR...FREE DRUG & /4-CHLOROHIPPURIC ACID/ EXCRETED IN URINE /HUMAN, ORAL/...PRESENT IN HIGH CONCN IN KIDNEY, LIVER, MUSCLE, HEART, & BODY FAT, & IN LESSER CONCN IN LUNG & PLASMA /RATS, ORAL/.

AFTER ORAL ADMIN OF (14)C-CHLORMEZANONE, ABOUT 74% OF DOSE WAS EXCRETED INTO URINE OF RATS WITHIN 24 HR & 21% INTO URINE OF MICE WITHIN 2 HR. BILIARY EXCRETION OF RADIOACTIVITY WAS ABOUT 10% OF DOSE IN RATS.

Cellular LocationsCytoplasm

用途と製造

Uses · 2 件

MEDICATION

Used in the management of anxiety and in the treatment of muscle spasm.

Methods of ManufacturingPREPN STARTING WITH 4-CHLOROBENZYLIDENEMETHYLAMINE: SURREY ET AL, J AM CHEM SOC 80, 3469 (1958): BRIT PAT 815,203 (1959 TO STERLING DRUG).
Formulations/PreparationsORAL: TABLETS 100 & 200 MG
Use ClassificationPharmaceuticals

応用分野

解説クロルメザノンマイナートランキライザ (→向精神薬 ) のなかで筋弛緩作用が比較的強いものの一つである。作用はメプロバメートに似ているが,化学構造はかなり異なる。静穏筋弛緩剤とも呼ばれることがあり,臨床的には腰背痛に用いられることが多い。ブリタニカ国際大百科事典 小項目事典 ブリタニカ

使用Chlormezanone improves the emotional state of the patient, relieving moderate anxiety and stress. However, it has a number of side effects, and because it does not have any advantage over other anxiolytics, it is rarely used in practice.

上流・下流製品情報

上流原料

3-メルカプトプロピオン酸4-クロロベンズアルデヒド

下流製品

whitener WG for woolケタミン·塩酸塩
補足説明 · 1 件

定義ChEBI: A 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions.